Theramex Says Currently Considering CMA's Decision, In Particular Whether And How Best To Address Competition Concerns Regarding Deal With Viatris; "Remains Committed To Offering Women Choice To Make Empowered Decisions About HRT At Competitive Prices For NHS"; Phase 1 Of CMA's Decision To Have No Impact On Co's Ability To Supply Existing HRT Products In UK
- Reuters